Meningioma in patients exposed to progestin drugs: results from a real-life screening program.
Thomas SamoyeauCorentin ProvostAlexandre RouxLaurence LegrandEdouard DezamisGenevieve Plu-BureauJohan PalludCatherine OppenheimJoseph BenzakounPublished in: Journal of neuro-oncology (2022)
Systematic MR screening in progestin-exposed patients uncovers small and multiple meningiomas, which can be managed conservatively, decreasing in size after progestin discontinuation. The high rate of meningiomas after CPA exposure reinforces the need for systematic screening. For NA and CMA, further studies are needed to identify patients most likely to benefit from screening.